Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 15

Results For "NGO"

986 News Found

NATCO announces launch of Pomalidomide capsules in US
News | March 05, 2026

NATCO announces launch of Pomalidomide capsules in US

It is also approved for?AIDS-related Kaposi sarcoma?after failure of highly active antiretroviral therapy, as well as for HIV-negative adult patients with Kaposi sarcoma


Ind-Swift earns EcoVadis silver medal for sustainability excellence
Sustainability | March 05, 2026

Ind-Swift earns EcoVadis silver medal for sustainability excellence

The Silver Medal recognizes strong performance across sustainability, ethics, environment, labour & human rights, and responsible procurement


Teva and Blackstone Life Sciences strike $400m deal to advance promising IBD therapy
R&D | March 05, 2026

Teva and Blackstone Life Sciences strike $400m deal to advance promising IBD therapy

The funding will be spread over four years, with BXLS also eligible for regulatory and commercial milestones, plus royalties on worldwide sales


Moderna strikes $950 million global settlement with Arbutus & Genevant, clears legal hurdles for vaccine pipeline
News | March 05, 2026

Moderna strikes $950 million global settlement with Arbutus & Genevant, clears legal hurdles for vaccine pipeline

Moderna will appeal to the Federal Circuit to assert that its government-contractor immunity limits liability under federal law


FDA nod to YUVIWEL, first once-weekly treatment for kids with achondroplasia
News | March 03, 2026

FDA nod to YUVIWEL, first once-weekly treatment for kids with achondroplasia

Achondroplasia, a rare genetic disorder, causes skeletal dysplasia and often increases the risk of muscular, neurological, and cardiorespiratory complications


Roche’s Fenebrutinib moves closer to being first BTK inhibitor for relapsing and progressive MS
Clinical Trials | March 02, 2026

Roche’s Fenebrutinib moves closer to being first BTK inhibitor for relapsing and progressive MS

Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology


Synthekine teams up with Merck to test breakthrough lung cancer combo
Biotech | February 28, 2026

Synthekine teams up with Merck to test breakthrough lung cancer combo

The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line


Lupin’s Vinita Gupta honoured as CNBC Changemaker for revolutionising U.S. healthcare access
People | February 28, 2026

Lupin’s Vinita Gupta honoured as CNBC Changemaker for revolutionising U.S. healthcare access

Vinita has made expansion in the U.S. a core pillar of Lupin’s worldwide growth strategy


Merck’s KEYTRUDA shows significant survival boost in platinum-resistant ovarian cancer
Clinical Trials | February 28, 2026

Merck’s KEYTRUDA shows significant survival boost in platinum-resistant ovarian cancer

KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients